Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.58 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | PREP | P48147 | 2/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5696187 | 0.97 | DPP4 (0.58) | DPP4CTSKCTSSCTSLCTSB | |
| SCHEMBL3605568 | 0.97 | DPP4 (0.58) | DPP4CTSKCTSSCTSLCTSB | |
| SCHEMBL8301687 | 0.97 | DPP4 (0.58) | DPP4CTSKCTSSCTSLCTSB | |
| SCHEMBL5696186 | 0.97 | DPP4 (0.58) | DPP4CTSKCTSSCTSLCTSB | |
| SCHEMBL9003137 | 0.97 | DPP4 (0.58) | DPP4CTSKCTSSCTSLCTSB | |
| SCHEMBL5053509 | 0.97 | DPP4 (0.58) | DPP4CTSKCTSSCTSLCTSB | |
| SCHEMBL3612579 | 0.92 | CTSK (0.54) | DPP4CTSKCTSSCTSLCTSB | |
| SCHEMBL5047656 | 0.89 | DPP4 (0.53) | DPP4CTSKCTSSCTSLCTSB | |
| SCHEMBL5644618 | 0.85 | DPP4 (0.62) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL14602196 | 0.85 | DPP4 (0.62) | DPP4PREPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081701-A1 | FAP inhibitors | FAP, APC, SERPINB1 | DPP4 256/4885CTSK 170/4885CTSS 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.